HGH Fragment 176-191 (HGH Frag) record · updated 6h ago
HGH Fragment 176-191 is a synthetic C-terminal fragment of human growth hormone studied for its lipolytic (fat-burning) effects without the growth-promoting actions of full GH.
Development stage
where HGH Fragment 176-191 (HGH Frag) sits between preclinical work and regulatory approval- 1CurrentPreclinicalAnimal / in-vitro work
- 2Not reachedPhase 1Safety in humans
- 3Not reachedPhase 2Efficacy signal
- 4Not reachedPhase 3Confirmatory trials
- 5Not reachedApprovedCleared by a regulator
Stage is inferred from the highest trial phase in the indexed corpus and 18 registered trials. It describes the research record, not a recommendation.
Mass and formula from PubChem CID 172966176. No verified residue count for this compound.
| Study | Type | Year | Summary depth |
|---|---|---|---|
| Illegal and falsified medicines self-administrated in not approved post-cycle therapy after the cessation of anabolic-androgenic steroids - qualitative analysis. Finding10.5% of samples declared to contain substances used in PCT, n=601. | — | 2025 | Full text read0.80 |
What people are saying
anecdotal · not evidenceUnverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching HGH Fragment 176-191 (HGH Frag) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.